IL-18 could represent an interesting biomarker for lymphomagenesis in pSS, opening the novel opportunities for the early diagnosis of lymphoproliferative complications and the development of potential targeted therapies for pSS. This evidence concerns the gene IL18 and peeling skin syndrome.